Andrew Parker
Food and Nutrition
ZEALAND PHARMA
Netherlands
Biography
Prior to joining Zealand, Andrew Parker was General Partner and Scientific Director for Eclosion2. At the same time, he was CEO of Arisgen SA, an Eclosion2 portfolio company developing an oral peptide drug delivery technology. Andrew Parker worked as Vice President and Head of Exploratory Projects for Shire plc.
Research Interest
Prior to joining Zealand, Andrew Parker was General Partner and Scientific Director for Eclosion2. At the same time, he was CEO of Arisgen SA, an Eclosion2 portfolio company developing an oral peptide drug delivery technology. Andrew Parker worked as Vice President and Head of Exploratory Projects for Shire plc.
